Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937242 | 0.88 | MTNR1A (0.58) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL14487776 | 0.87 | MTNR1A (0.63) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL25896801 | 0.86 | MTNR1A (0.49) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL19709247 | 0.82 | MTNR1A (0.63) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL15242249 | 0.80 | MTNR1A (0.67) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL25290441 | 0.79 | MTNR1A (0.82) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL14962811 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL12479383 | 0.78 | MTNR1A (0.66) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL31194205 | 0.77 | MTNR1A (0.65) | MTNR1AMTNR1BHTR1DHTR1BHTR1F | |
| SCHEMBL31291618 | 0.77 | MTNR1A (0.57) | MTNR1AMTNR1BHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2018-09-27 | — | — | US | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 426/4885MTNR1B 892/4885HTR1D 3881/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR1D 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.